Immuno-Oncology

Single-agent nivolumab demonstrated a robust 5-year overall survival rate of 34% for heavily pretreated patients with metastatic melanoma who had not received prior ipilimumab.

Raffaele Califano, MD, consultant in medical oncology at the Christie NHS Foundation Trust and University Hospital of South Manchester, discuses the potential for immunotherapy in small-cell lung cancer (SCLC).

Efficacy and safety remained strong 2 years following treatment with nivolumab for patients with advanced, refractory, squamous non-small–cell lung cancer, with an indication that cytokine levels could predict long-term outcomes.

John Haanen, MD PhD, epartment of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, discussed the role of PD-L1 as a biomarker in lung cancer.

The FDA has granted nivolumab (Opdivo) a priority review for use in previously treated patients with classical Hodgkin lymphoma.

The FDA has granted a priority review designation to pembrolizumab (Keytruda) as a treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma.

Benjamin P. Levy, MD, assistant professor of Medicine, Hematology, and Medical Oncology at Mount Sinai Hospital, discusses how nivolumab (Opdivo) and pembrolizumab (Keytruda) have impacted the treatment landscape of non–small cell lung cancer.

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses why community oncologists should utilize immunotherapy agents to treat patients with renal cell carcinoma.

The FDA has granted a priority review to atezolizumab for the treatment of patients with locally advanced or metastatic non–small cell lung cancer who express PD-L1 and have progressed after a platinum-containing regimen.

Jonathan D. Schoenfeld, MD, discusses potential synergy between radiation therapy, given with or without chemotherapy, and immune checkpoint inhibitors in patients with squamous cell carcinoma of the head and neck.

The European Commission has approved nivolumab (Opdivo) for use in previously treated patients with advanced renal cell carcinoma.

The European Commission has approved nivolumab (Opdivo) for the treatment of patients with nonsquamous non–small cell lung cancer, regardless of PD-L1 levels.

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of Oncology and Medicine, Georgetown University School of Medicine, discusses the adjuvant use of ipilimumab (Yervoy) in patients with melanoma.

PD-1/PD-L1 should be the backbone of melanoma treatment for many patients, says Jason Luke, MD, an assistant professor of Medicine at the University of Chicago Medicine.

Edward Kim, MD, discusses the impact of nivolumab (Opdivo) and pembrolizumab (Keytruda) in non–small cell lung cancer, potential combinations, biomarkers, and ongoing research.

The future looks bright for immunotherapies and novel targeted approaches for patients with gliomas, many of which have already been developed for other types of cancer.

Immunotherapy should be considered along with VEGF and mTOR TKIs as a highly effective treatment modality for patients with metastatic renal cell carcinoma.

Tara C. Mitchell, MD, discusses what oncologists need to know about using immunotherapies in melanomaâ€â€

Sarah Goldberg, MD, MPH, discusses the efficacy of immunotherapies, PD-L1 as a biomarker, and how these therapies will continue to alter the treatment of patients with non–small cell lung cancer.

The combination of ipilimumab and nivolumab has received a positive recommendation from the CHMP, which suggests that the treatment is likely to gain European approval for patients with advanced melanoma.

Michael Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of patients with melanoma.

The European Medicines Agency validated an application for use of nivolumab (Opdivo) for previously treated patients with classical Hodgkin lymphoma), which officially begins the centralized review process for final approval of the drug in the European Union.

After nearly 30 years of research, tumor-infiltrating lymphocyte technology is being investigated as a means of producing personalized immunotherapy for patients with metastatic melanoma in a small clinical trial that may help open the door for broader application in other solid tumor types.

H. Thomas Temple, MD, explains where he sees the future of sarcoma going and what diagnostic technologies and therapeutic advancements he is most excited about.

Emerging agents targeting the PD1/PD-L1 pathway and the process of angiogenesis are shaping up to be promising options to break a 30-year drought in new therapies for patients with progressive metastatic urothelial bladder cancer.